IceCure Medical (ICCM) Stock Price, News & Analysis

Company Overview

IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation technology for the treatment of tumors. The company’s technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to more invasive surgical procedures.

Its primary product, the ProSense system, is designed to deliver controlled cryoablation through a thin probe inserted into a tumor under image guidance. The system has been developed for use in a range of tumor types, including breast, kidney, liver, lung and bone tumors, and has received regulatory clearances and approvals for certain indications in markets including the United States and other countries.

IceCure Medical is headquartered in Caesarea, Israel, and serves healthcare providers through commercial and distribution activities in international markets, including North America, Europe and Asia. The company’s products are intended for use by physicians in hospitals and other clinical settings, with applications spanning oncology and breast health.

Key Stats

• Today's Range: $1.60 to $1.82
• 50-Day Range: $1.59 to $3.51
• 52-Week Range: $1.56 to $42.00
• Volume: 320,564 shs
• Average Volume: 101,315 shs
• Market Capitalization: $5.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.50
• Consensus Rating: Hold

IceCure Medical Stock Analysis - MarketRank™

IceCure Medical scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

IceCure Medical has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

IceCure Medical has a consensus price target of $52.50, representing about 3,150.8% upside from its current price of $1.62.

Amount of Analyst Coverage

IceCure Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IceCure Medical are expected to grow in the coming year, from ($4.61) to ($3.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IceCure Medical is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IceCure Medical is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IceCure Medical has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.07% of the float of IceCure Medical has been sold short.

Short Interest Ratio / Days to Cover

IceCure Medical has a short interest ratio ("days to cover") of 1.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IceCure Medical has recently decreased by 4.73%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IceCure Medical does not currently pay a dividend.

Dividend Growth

IceCure Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.82

News Sentiment

IceCure Medical has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for IceCure Medical this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added IceCure Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IceCure Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.44% of the stock of IceCure Medical is held by insiders.

Percentage Held by Institutions

0.62% of the stock of IceCure Medical is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ICCM
• CIK: 1584371
• Web: www.icecure-medical.com
• Phone: 972-4623-0333
• Fax: 972-4623-0222
• Employees: 66
• Year Founded: 2006

Price Target and Rating

• Average Price Target for IceCure Medical: $52.50
• High Price Target: $75.00
• Low Price Target: $30.00
• Potential Upside/Downside: +3,150.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.06 million
• Net Margins: -427.67%
• Pretax Margin: -445.61%
• Return on Equity: -174.26%
• Return on Assets: -112.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $3.38 million
• Price / Sales: 1.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.72 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 3,430,000
• Free Float: 3,342,000
• Market Cap: $5.54 million
• Optionable: Not Optionable
• Beta: 0.45